Ketorolac, 10 mg 10 pcs

Ketorolac has a pronounced analgesic effect, also has anti-inflammatory and moderate antipyretic effects.

The mechanism of action is associated with non-selective inhibition of cyclooxygenase 1 and 2 enzyme activity, mainly in peripheral tissues, the consequence of which is inhibition of prostaglandin biosynthesis – modulators of pain sensitivity, thermoregulation and inflammation. Ketorolac is a racemic mixture of [-]S and [+]R enantiomers, the analgesic effect being due to the [-]S form.

The drug does not affect opioid receptors, does not depress respiration, is not addictive, and has no sedative or anxiolytic action.

In terms of analgesic effect the drug is comparable to morphine and is significantly superior to other NSAIDs.

After oral administration, the onset of analgesic effect is noted in 1 hour respectively, the maximum effect is reached after 1-2 hours.

Indications

Moderate to severe pain syndrome:

postoperative pain,
joint pain due to injuries with ligament rupture,
dislocations,
sprains; back and muscle pain.

Pharmacological effect

Ketorolac has a pronounced analgesic effect and also has anti-inflammatory and moderate antipyretic effects.

The mechanism of action is associated with non-selective inhibition of the activity of the enzyme cyclooxygenase 1 and 2, mainly. in peripheral tissues, resulting in inhibition of the biosynthesis of prostaglandins – modulators of pain sensitivity, thermoregulation and inflammation. Ketorolac is a racemic mixture of [-]S and [+]R enantiomers, with the analgesic effect due to the [-]S form.

The drug does not affect opioid receptors, does not depress respiration, does not cause drug dependence, and does not have a sedative or anxiolytic effect.

The strength of the analgesic effect is comparable to morphine, significantly superior to other NSAIDs.

After oral administration, the onset of analgesic action is noted after 1 hour, the maximum effect is achieved after 1-2 hours.

Special instructions

Use with caution in patients with impaired liver and kidney function, chronic heart failure, arterial hypertension, in patients with a history of erosive and ulcerative lesions of the gastrointestinal tract and bleeding from the gastrointestinal tract, a history of blood clotting disorders.

Caution should be exercised when using ketorolac in the postoperative period in cases where particularly careful hemostasis is required (including after resection of the prostate gland, tonsillectomy, in cosmetic surgery), as well as in elderly patients, because The half-life of ketorolac is prolonged and plasma clearance may be reduced. In this category of patients, it is recommended to use ketorolac in doses that are at the lower limit of the therapeutic range.

If symptoms of liver damage, skin rash, or eosinophilia appear, ketorolac should be discontinued. Ketorolac is not indicated for use in chronic pain syndrome.

Impact on the ability to drive vehicles and operate machinery
If drowsiness, dizziness, insomnia or depression appear during treatment with ketorolac, special care must be taken when engaging in potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Active ingredient

Ketorolac

Composition

1 tablet contains ketorolac tromethamine – 10 mg.

Contraindications

hypersensitivity (including to aspirin and other NSAIDs),
nasal polyps,
angioedema,
bronchospasm,
bronchial asthma,
stomach and duodenal ulcers,
renal dysfunction,
hypovolemia,
dehydration,
high risk of postoperative bleeding or incomplete bleeding control,
hematopoiesis disorder,
bleeding in the brain,
early childhood (up to 2 years).

Side Effects

nausea,
stomach ache,
diarrhea,
drowsiness,
headache,
anxiety,
damage to the mucous membrane of the stomach and intestines,
pain at the injection site.

Interaction

When ketorolac is used concomitantly with other NSAIDs, additive side effects may develop; with pentoxifylline, anticoagulants (warfarin, heparin in low doses) – the risk of bleeding may increase; with ACE inhibitors – there may be an increased risk of developing renal dysfunction; with probenecid – the plasma concentration of ketorolac and its half-life increase; with lithium preparations – a decrease in the renal clearance of lithium and an increase in its concentration in plasma is possible; with furosemide – reducing its diuretic effect.

When using ketoralac, the need for the use of opioid analgesics for pain relief is reduced.

Overdose

Symptoms (with a single dose): abdominal pain, nausea, vomiting, erosive and ulcerative lesions of the gastrointestinal tract, impaired renal function, metabolic acidosis.

Treatment: symptomatic (maintaining vital functions of the body). Dialysis is ineffective.

Storage conditions

In a place protected from light at a temperature of 15 to 25 ° C.

Keep out of the reach of children.

Shelf life

2 years

Manufacturer

Sintez, Russia